Current Clinical Trials

Rank Status Study
1 Unknown † Laboratory Study of Cannabidiol on the Effects of Smoked Marijuana

Condition: Smoking, Marijuana
Intervention: Drug: cannabidiol
2 Unknown † Safety and Efficacy of Cannabidiol for Grade I/II Acute Graft Versus Host Disease (GVHD) After Allogeneic Stem Cell Transplantation

Condition: Graft Versus Host Disease
Intervention: Drug: Cannabidiol
3 Not yet recruiting Sublingual Cannabidiol for Anxiety

Condition: Anxiety
Intervention: Drug: Cannabidiol
4 Unknown † Cannabidiol for Graft Versus Host Disease (GVHD) Prophylaxis in Allogeneic Stem Cell Transplantation

Condition: Graft Versus Host Disease
Intervention: Drug: Oral Cannabidiol
5 Completed Cannabidiol for Inflammatory Bowel Disease

Conditions: Crohn’s Disease;   Ulcerative Colitis
Interventions: Drug: cannabidiol;   Drug: placebo in drops
6 Active, not recruiting Cannabidiol Expanded Access Study in Medically Refractory Sturge-Weber Syndrome

Condition: Sturge-Weber Syndrome
Intervention: Drug: Cannabidiol
7 Active, not recruiting Cannabidiol Oral Solution as an Adjunctive Treatment for Treatment-resistant Seizure Disorder

Condition: Seizures
Intervention: Drug: Cannabidiol Oral Solution
8 Completed Cannabidiol Oral Solution in Pediatric Subjects With Treatment- Resistant Seizure Disorders

Condition: Seizures
Intervention: Drug: Cannabidiol Oral Solution
9 Completed Study to Test the Safety and Efficacy of Cannabidiol as a Treatment Intervention for Opioid Relapse

Condition: Opiate Addiction
Interventions: Drug: Cannabidiol;   Drug: Fentanyl
10 Not yet recruiting Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Subjects With Inadequately Controlled Dravet Syndrome

Condition: Dravet Syndrome
Interventions: Drug: Cannabidiol Oral Solution;   Drug: Placebo Solution
11 Not yet recruiting Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Subjects With Inadequately Controlled Lennox-Gastaut Syndrome

Condition: Lennox-Gastaut Syndrome
Interventions: Drug: Cannabidiol Oral Solution;   Drug: Placebo Solution
12 Completed
Has Results		 Acute and Short-term Effects of Cannabidiol Admin on Cue-induced Craving in Drug-abstinent Heroin Dependent Humans

Condition: Opiate Addiction
Interventions: Drug: Cannabidiol 400;   Drug: Cannabidiol 800;   Drug: Control
13 Active, not recruiting Cannabidiol (CBD) to 27 Patients (Aged 2 Years – 19 Years) With Drug Resistant Epilepsy

Condition: Epilepsy
Intervention: Drug: Cannabidiol
14 Recruiting Cannabidiol and Cocaine Craving/Dependence

Conditions: Substance Use Disorder;   Cocaine Dependence;   Withdrawal From Addictive Substance; Detoxification
Intervention: Drug: Cannabidiol
15 Not yet recruiting Cannabidiol Oral Solution for The Treatment of Subjects With Prader-Willi Syndrome

Condition: Prader-Willi Syndrome
Interventions: Drug: Cannabidiol;   Drug: Placebo
16 Recruiting A Study of Tolerability and Efficacy of Cannabidiol on Tremor in Parkinson’s Disease

Condition: Parkinson’s Disease
Interventions: Drug: cannabidiol;   Drug: placebo
17 Active, not recruiting Cannabidiol and Emotional Stimuli

Condition: Drug Addiction
Interventions: Drug: Cannabidiol;   Drug: Placebo
18 Completed
Has Results		 Study to Assess the Effect of Cannabidiol on Liver Fat Levels in Subjects With Fatty Liver Disease.

Condition: Fatty Liver
Intervention: Drug: Cannabidiol
19 Not yet recruiting Cannabidiol for the Treatment of Severe (Grades III/IV) Acute Graft-versus-host Disease

Condition: Acute-graft-versus-host Disease
Interventions: Drug: Cannabidiol;   Drug: Methylprednisolone;   Drug: Calcineurin inhibitor
20 Completed A Clinical Trial on the Antipsychotic Properties of Cannabidiol

Conditions: Schizophrenia;   Psychotic Disorders
Interventions: Drug: Placebo/Cannabidiol;   Drug: Cannabidiol/Placebo
21 Recruiting A Four-week Clinical Trial Investigating Efficacy and Safety of Cannabidiol as a Treatment for Acutely Ill Schizophrenic Patients

Condition: Schizophrenia
Interventions: Drug: Cannabidiol;   Drug: Olanzapine;   Drug: Placebo Cannabidiol;   Drug: Placebo Olanzapine
22 Not yet recruiting Cannabidiol as a New Intervention for Amphetamine Dependence

Condition: Amphetamine Addiction
Interventions: Drug: CBD;   Drug: Placebo;   Drug: AMPH
23 Active, not recruiting Cannabidiol Oral Solution for Treatment of Refractory Infantile Spasms

Condition: Spasms, Infantile
Intervention: Drug: Cannabidiol Oral Solution
24 Available Treatment of Drug Resistant Epilepsy

Condition: Epilepsy
Interventions: Drug: cannabidiol;   Other: Blood Test
25 Recruiting Cannabidiol as a Different Type of an Antipsychotic: Drug Delivery and Interaction Study

Condition: Schizophrenia
Interventions: Drug: Cannabidiol CR;   Drug: Cannabidiol;   Drug: Amisulpride;   Drug: Olanzapine;   Drug: Quetiapine;   Drug: Risperidone;   Drug: Placebo
26 Available Study of Cannabidiol for Drug-Resistant Epilepsies

Condition: Drug Resistant Epilepsy
Intervention: Drug: Cannabidiol
27 Recruiting GWPCARE2 A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet Syndrome

Conditions: Epilepsy;   Dravet Syndrome
Interventions: Drug: GWP42003-P;   Drug: Placebo Control
28 Active, not recruiting Cannabidiol: a Novel Intervention for Cannabis Use Problems?

Condition: Cannabis Use Disorder
Interventions: Drug: Cannabidiol;   Drug: Placebo
29 Active, not recruiting Trial of Cannabidiol (CBD; GWP42003-P) for Infantile Spasms (GWPCARE7)

Condition: Infantile Spasms
Intervention: Drug: GWP42003-P
30 Available Safety and Tolerability of Cannabidiol in Subjects With Drug Resistant Epilepsy

Condition: Epilepsy
Intervention: Drug: Cannabidiol
31 Enrolling by invitation An Open Label Extension Study of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet or Lennox-Gastaut Syndromes

Conditions: Epilepsy;   Dravet Syndrome;   Lennox-Gastaut Syndrome
Intervention: Drug: GWP42003-P
32 Active, not recruiting Phase 3 Trial of Cannabidiol (CBD; GWP42003-P) for Infantile Spasms: Open-label Extension Phase (GWPCARE7)

Condition: Infantile Spasms
Intervention: Drug: GWP42003-P
33 Completed A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults

Conditions: Epilepsy;   Lennox-Gastaut Syndrome
Interventions: Drug: GWP42003-P;   Drug: Placebo Control
34 Not yet recruiting Extended Use of Cannabidiol for the Prevention of Graft-versus-host-disease

Condition: Graft vs Host Disease
Interventions: Drug: Cannabidiol;   Drug: cyclosporine;   Drug: Methotrexate
35 Completed A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults

Conditions: Epilepsy;   Lennox-Gastaut Syndrome
Interventions: Drug: GWP42003-P;   Drug: Placebo control
36 Unknown † Cannabidiol (CBD) for the Management of Cannabis Withdrawal: A Phase II Proof of Concept Study

Condition: Cannabis Use Disorder
Intervention: Drug: CBD
37 Available Cannabidiol for Pediatric Epilepsy (Compassionate Use)

Condition: Refractory Childhood Epilepsy
Intervention: Drug: cannabidiol (CBD)
38 Recruiting Cannabidiol Treatment in Patients With Early Psychosis

Conditions: Schizophrenia;   Schizoaffective Disorder
Interventions: Drug: Cannabidiol;   Drug: Placebo
39 Not yet recruiting Enhancing Recovery in Early Schizophrenia

Condition: Schizophrenia
Interventions: Drug: Cannabidiol as add-on;   Drug: Placebo as add-on
40 Completed Antiepileptic Efficacy Study of GWP42003-P in Children and Young Adults With Dravet Syndrome (GWPCARE1)

Conditions: Epilepsy;   Dravet Syndrome
Interventions: Drug: GWP42003-P;   Drug: Placebo control